Brief: Imugene Ltd Says FDA Grants Fast Track Designation To Co's Azer-CEL For CLL/SLL And MZL
09/06/2026 02:29
BRIEF-Imugene Ltd Says FDA Grants Fast Track Designation To Co's Azer-CEL For CLL/SLL And MZL June 9 (Reuters) - Imugene Ltd IMU.AX:
AZER-CEL GRANTED FDA FAST TRACK DESIGNATION FOR CLL AND MZL
FDA GRANTS FAST TRACK DESIGNATION TO IMUGENE'S AZER-CEL FOR CLL/SLL AND MZL
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement